Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsons ProductsBOM:543399 -1.21%82 Return-on-Tangible-Equity is 2.91% as of Mar. 2026, which is 85% below its 10-year median of 19.81. GuruFocus rates BOM:543399 with a GF Score™ of 82/100 and a GF Value™ of ₹572.16 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Tarsons Products ranks worse than 54.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tarsons Products's annualized net income for the quarter that ended in Mar. 2026 was ₹167 Mil. Tarsons Products's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹5,750 Mil. Therefore, Tarsons Products's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.91%.
The historical rank and industry rank for Tarsons Products's Return-on-Tangible-Equity or its related term are showing as below:
BOM:543399'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.51 Med: 19.81 Max: 31.21
Current: 2.52
During the past 8 years, Tarsons Products's highest Return-on-Tangible-Equity was 31.21%. The lowest was 2.51%. And the median was 19.81%.
BOM:543399's Return-on-Tangible-Equity is ranked worse than 54.22% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs BOM:543399: 2.52
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tarsons Products Return-on-Tangible-Equity Related Terms
Tarsons Products Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Tarsons Products's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543399 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Tarsons Products's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsons Products Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tarsons Products's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tarsons Products's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.91% mean?
Tarsons Products (BOM:543399) has a Return-on-Tangible-Equity of 2.91% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tarsons Products and its competitors. This is 85% below median its historical median of 19.81. Over the past decade, Tarsons Products' Return-on-Tangible-Equity has ranged from 2.51 to 31.21. According to the industry distribution chart, Tarsons Products ranks #411 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 54.2%.
Is Tarsons Products' Return-on-Tangible-Equity too high?
Tarsons Products' current Return-on-Tangible-Equity of 2.91% is 85% below median its 10-year median of 19.81. Over the past 10 years, this metric has ranged from a low of 2.51 to a high of 31.21. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Tarsons Products' value of 2.91% is 28.2% below this industry median. Based on the distribution chart, Tarsons Products ranks #411 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tarsons Products has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tarsons Products ranks #411 out of 758 companies for Return-on-Tangible-Equity. This places Tarsons Products in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. Tarsons Products' value of 2.91% is 28.2% below this benchmark. Historically, Tarsons Products' own Return-on-Tangible-Equity has ranged from 2.51 to 31.21 over the past decade. While the company's 10-year median is 19.81 vs. the industry median of 4.06, Tarsons Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsons Products's current Return-on-Tangible-Equity of 2.91% is 28.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tarsons Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsons Products's current Return-on-Tangible-Equity is 2.91%, which is 85% below median its own 10-year median of 19.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (BOM:543399) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹572.16, compared to a current price of ₹313.65 — trading 45.2% below its estimated fair value. The current Return-on-Tangible-Equity is 2.91%, which is 85% below median its 10-year median of 19.81 and 28.2% below the Medical Devices & Instruments industry median of 4.06. Tarsons Products' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tarsons Products (BOM:543399), the current Return-on-Tangible-Equity is 2.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsons Products (BOM:543399) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued.
The current stock price of ₹313.65 is trading 45.2% below its estimated GF Value™ of ₹572.16.
GuruFocus considers Tarsons Products to be Significantly Undervalued.
Key valuation signals for BOM:543399:
Return-on-Tangible-Equity: 2.91% (85% below median its 10-year median of 19.81)
GF Value™: ₹572.16 vs. price of ₹313.65 (45.2% below fair value)
Industry Position: 28.2% below the Medical Devices & Instruments median (#411 of 758)
No single metric tells the full story. See the BOM:543399 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
82GF Score
Get the complete analysis for BOM:543399
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543399 has been successfully added to your 
